Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Journals » World Heart Journal » Volume 13 Issue 1 Articles » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Fetal Alcohol Syndrome: Recognition, Differential Diagnosis and Long-Term Effects
$73.80
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to The Effect of Spironolactone in Reducing Ventricular Arrhythmia in ICD-Implanted Patients (pp. 61-68)
Tell A Friend
 
Tell someone you know about this product.
The Effect of Spironolactone in Reducing Ventricular Arrhythmia in ICD-Implanted Patients (pp. 61-68) $0.00
Authors:  Chonthicha Tanking and Thoranis Chantrarat
Abstract:
Background: In patients with implantable cardioverter defibrillator (ICD), ventricular arrhythmia could lead to device shock, resulting in deleterious effects such as mortality and heart failure hospitalizations. The beneficial effect of spironolactone in reducing incidence of ventricular arrhythmia has been proposed. However, there is still insufficient confirmed evidence to prove this hypothesis.
Subjects and methods: This prospective cohort study was performed with data collection from patients who presented at heart clinic. Patients implanted with defibrillator, left ventricular ejection fraction less than 50%, functional class I-III were enrolled.
Results: A total of 110 patients were included. There were 48 patients in spironolactone group and 62 patients in non-spironolactone group. Mean follow-up time was about 6 months. The incidence rate ratio (IRR) of total episodes was significantly lower in the spironolactone group (IRR = 0.65 (95%CI 0.57-0.74, p-value < 0.001). The same trend was observed for NSVT and VT (IRR = 0.66, 0.36 with p < 0.001, 0.012, respectively). The IRR of ICD related total therapies was lower in the spironolactone group, with no statistical significance (IRR = 0.55, p = 0.156). Left ventricular ejection fraction less than 35%, male gender, advanced age, diabetes and hypertension were significant risk factors for developing ventricular arrhythmia events.
Conclusion: In implantable cardioverter defibrillator implanted patients with left ventricular dysfunction, spironolactone could be a protective factor for a significant reduction of ventricular arrhythmia events. There is a trend towards lower total therapy. Risk factors for developing ventricular arrhythmia events are left ventricular ejection fraction less than 35%, male gender, advanced age, diabetes and hypertension. 


Available Options:
Version:

  Open Access item.
  Click below PDF icon for free download.

  

This is an Open Access item. Click above PDF icon for free download.
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
03.Chronic Disease and Disability: The Pediatric Lung
04.Fruit and Vegetable Consumption and Health: New Research
05.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2

Nova Science Publishers
© Copyright 2004 - 2022

The Effect of Spironolactone in Reducing Ventricular Arrhythmia in ICD-Implanted Patients (pp. 61-68)